Photo: Taken from Prensa Latina

New Drug Developed in Russia for Diabetes

Russian scientists at the Vorozhtsov Institute of Organic Chemistry in Novosibirsk have created a new compound. For the treatment of metabolic syndrome and type 2 diabetes, the Nauka.mail website reported Wednesday.

According to the article, the new drug simultaneously reduces blood sugar and cholesterol levels. It is a molecule created by combining a phenylpropanoic acid derivative with natural terpenoids. Also organic compounds found in plants, pine needles, and essential oils.

The new compound acts on PPAR receptors, which regulate carbohydrate and lipid metabolism. Only two drugs of this type have been approved worldwide. Both are manufactured abroad: in India and China.

These types of drugs are not produced in Russia. So the Novosibirsk scientists’ development has no domestic alternative.

Moreover the molecule’s structure is divided into a pharmacophore. Which interacts directly with the receptor’s active site, and a lipophilic fragment. Also which facilitates both transport across the cell membrane and additional hydrophobic interactions with the receptor’s allosteric site.

Experiments in mice demonstrated that the compound effectively reduces glucose and cholesterol levels without negatively impacting the liver, unlike some foreign analogs. The drug has a cumulative effect, which distinguishes it from existing medications.

Currently, scientists are testing the compounds in cell cultures to assess their receptor affinity and minimize potential side effects. The researchers have already obtained patents and are seeking investors for preclinical trials. If the development is successful, Russia will become the third country in the world to produce drugs in the glitazar class.

Glitazars are drugs that simultaneously activate two types of PPAR receptors (alpha and gamma). Allowing them to influence both glucose and cholesterol levels.

With information from Prensa Latina

Radio Angulo
Latest posts by Radio Angulo (see all)